...
首页> 外文期刊>Familial cancer >Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene
【24h】

Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene

机译:MUTYH和DNA错配修复基因均发生突变的人患结直肠癌的风险

获取原文
获取原文并翻译 | 示例

摘要

The base excision repair protein, MUTYH, functionally interacts with the DNA mismatch repair (MMR) system. As genetic testing moves from testing one gene at a time, to gene panel and whole exome next generation sequencing approaches, understandin g the risk associated with co-existence of germline mutations in these genes will be important for clinical interpretation and management. From the Colon Cancer Family Registry, we identified 10 carriers who had both a MUTYH mutation (6 with c.1187G > A p.(Gly396Asp), 3 with c.821G > A p.(Arg274Gln), and 1 with c.536A > G p.(Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 375 carriers of a single (monoallelic) MUTYH mutation alone, and 469 carriers of a MMR gene mutation alone. Of the 10 carriers of both gene mutations, 8 were diagnosed with colorectal cancer. Using a weighted cohort analysis, we estimated that risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was substantially higher than that for carriers of a MUTYH mutation alone [hazard ratio (HR) 21.5, 95 % confidence interval (CI) 9.19-50.1; p < 0.001], but not different from that for carriers of a MMR gene mutation alone (HR 1.94, 95 % CI 0.63-5.99; p = 0.25). Within the limited power of this study, there was no evidence that a monoallelic MUTYH gene mutation confers additional risk of colorectal cancer for carriers of a MMR gene mutation alone. Our finding suggests MUTYH mutation testing in MMR gene mutation carriers is not clinically informative.
机译:碱基切除修复蛋白MUTYH在功能上与DNA错配修复(MMR)系统相互作用。随着基因测试从一次测试一个基因转移到基因组和整个外显子组下一代测序方法,了解与这些基因中的种系突变共存相关的风险对于临床解释和管理非常重要。从结肠癌家庭登记处,我们确定了10个携带者都具有MUTYH突变(6个携带c.1187G> A p。(Gly396Asp),3个携带c.821G> A p。(Arg274Gln),1个携带c.536A。 > G p。(Tyr179Cys))和MMR基因突变(MLH1中为3,MSH2中为6,PMS2中为1),单个MUTYH突变(单等位基因)单独的375个携带者和MMR基因突变的单独469个载体。在这两个基因突变的10个携带者中,有8个被诊断出患有大肠癌。使用加权队列分析,我们估计同时携带MUTYH和MMR基因突变的携带者的结直肠癌风险大大高于仅携带MUTYH突变的携带者[风险比(HR)21.5,95%置信区间(CI) )9.19-50.1; p <0.001],但与单独的MMR基因突变的携带者没有区别(HR 1.94,95%CI 0.63-5.99; p = 0.25)。在这项研究的有限能力范围内,没有证据表明单等位基因MUTYH基因突变会给单独的MMR基因突变携带者带来大肠癌的额外风险。我们的发现表明,在MMR基因突变携带者中进行MUTYH突变测试没有临床意义。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号